Cancer-associated fibroblasts mediate resistance to anti-EGFR therapies in cancer

被引：6

作者：

Dai, Shuang ^{[1
,2
]}

Liu, Yingtong ^{[1
,3
]}

Liu, Zheran ^{[4
]}

Li, Ruidan ^{[4
]}

Luo, Feng ^{[1
,2
]}

Li, Yan ^{[1
,2
]}

Dai, Lei ^{[5
]}

Peng, Xingchen ^{[4
]}

机构：

[1] Sichuan Univ, West China Hosp, Canc Ctr, Dept Med Oncol, Chengdu, Sichuan, Peoples R China

[2] Sichuan Univ, West China Hosp, Lung Canc Ctr, Chengdu, Sichuan, Peoples R China

[3] Chengdu Univ Tradit Chinese Med, Chengdu 610041, Sichuan, Peoples R China

[4] Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China

[5] Sichuan Univ, West China Hosp, Collaborat Innovat Ctr Biotherapy, State Key Lab Biotherapy, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China

来源：

PHARMACOLOGICAL RESEARCH | 2024年 / 206卷

基金：

中国国家自然科学基金;

关键词：

Epidermal growth factor receptor; Cancer-associated fibroblast; Tumor microenvironment; Anti-EGFR therapy; resistance; GROWTH-FACTOR RECEPTOR; PANCREATIC-CANCER; PHASE-II; ERBB FAMILY; LUNG ADENOCARCINOMA; THERAPEUTIC TARGET; TGF-ALPHA; HEAD; TEMOZOLOMIDE; INHIBITION;

D O I：

10.1016/j.phrs.2024.107304

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Over the last decade, epidermal growth factor receptor (EGFR)-targeted therapies have transformed the treatment landscape for patients with advanced solid tumors. Despite these advances, resistance to anti-EGFR therapies is still a significant clinical challenge. While cell-autonomous mechanisms of resistance are welldocumented, they do not fully elucidate the complexity of drug resistance. Cancer-associated fibroblasts (CAFs), key mediators within the tumor microenvironment (TME), have emerged as pivotal players in cancer progression and chemoresistance. Recent evidence implicates CAFs in resistance to anti-EGFR therapies, suggesting they may undermine treatment efficacy. This review synthesizes current data, highlighting the critical role of CAFs in resistance pathogenesis and summarizing recent therapeutic strategies targeting CAFs. We underscore the challenges and advocate for the exploration of CAFs as a potential dual-targeted approach.

引用

页数：10

共 91 条

[1]

Affo S, 2021, CANCER CELL, V39, P866, DOI 10.1016/j.ccell.2021.03.012

[2] Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies [J].

Apicella, Maria ;

Giannoni, Elisa ;

Fiore, Stephany ;

Ferrari, Karin Johanna ;

Fernandez-Perez, Daniel ;

Isella, Claudio ;

Granchi, Carlotta ;

Minutolo, Filippo ;

Sottile, Antonino ;

Comoglio, Paolo Maria ;

Medico, Enzo ;

Pietrantonio, Filippo ;

Volante, Marco ;

Pasini, Diego ;

Chiarugi, Paola ;

Giordano, Silvia ;

Corso, Simona .

CELL METABOLISM, 2018, 28 (06) :848-+

[3] Therapeutic Targeting of the Tumor Microenvironment [J].

Bejarano, Leire ;

Jordao, Marta J. C. ;

Joyce, Johanna A. .

CANCER DISCOVERY, 2021, 11 (04) :933-959

[4] DIVERSITY AND BIOLOGY OF CANCER-ASSOCIATED FIBROBLASTS [J].

Biffi, Giulia ;

Tuveson, David A. .

PHYSIOLOGICAL REVIEWS, 2021, 101 (01) :147-176

[5] Epidermal growth factor receptor as a therapeutic target in head and neck cancer [J].

Bonner, JA ;

De los Santos, J ;

Waksal, HW ;

Needle, MN ;

Trummel, HQ ;

Raisch, KP .

SEMINARS IN RADIATION ONCOLOGY, 2002, 12 (03) :11-20

[6] Tapered dose versus constant drug exposure to anti-EGFR drugs on head-and-neck cancer xenografts. A comparison between cetuximab and gefitinib [J].

Bozec, Alexandre ;

Formento, Patricia ;

Fischel, Jean-Louis ;

Etienne-Grimaldi, Marie-Christine ;

Milano, Gerard .

ORAL ONCOLOGY, 2010, 46 (03) :172-177

[7] Activated fibroblasts in cancer: Perspectives and challenges [J].

Caligiuri, Giuseppina ;

Tuveson, David A. .

CANCER CELL, 2023, 41 (03) :434-449

[8] EGF-R small inhibitors and anti-EGF-R antibodies: Advantages and limits of a new avenue in anticancer therapy [J].

Caraglia, Michele ;

Marra, Monica ;

Meo, Giusy ;

Addeo, Raffaele ;

Tagliaferri, Pierosandro ;

Budillon, Alfredo .

RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2006, 1 (02) :209-222

[9] TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer [J].

Carey, Lisa A. ;

Rugo, Hope S. ;

Marcom, P. Kelly ;

Mayer, Erica L. ;

Esteva, Francisco J. ;

Ma, Cynthia X. ;

Liu, Minetta C. ;

Storniolo, Anna Maria ;

Rimawi, Mothaffar F. ;

Forero-Torres, Andres ;

Wolff, Antonio C. ;

Hobday, Timothy J. ;

Ivanova, Anastasia ;

Chiu, Wing-Keung ;

Ferraro, Madlyn ;

Burrows, Emily ;

Bernard, Philip S. ;

Hoadley, Katherine A. ;

Perou, Charles M. ;

Winer, Eric P. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2615-2623

[10] Single-cell and spatial transcriptomics reveal POSTN+ cancer-associated fibroblasts correlated with immune suppression and tumour progression in non-small cell lung cancer [J].

Chen, Chao ;

Guo, Qiang ;

Liu, Yang ;

Hou, Qinghua ;

Liao, Mengying ;

Guo, Yanying ;

Zang, Yupeng ;

Wang, Fei ;

Liu, Huanyu ;

Luan, Xinyu ;

Liang, Yanling ;

Guan, Zhuojue ;

Li, Yanling ;

Liu, Haozhen ;

Dong, Xuan ;

Zhang, Xiuqing ;

Liu, Jixian ;

Xu, Qumiao .

CLINICAL AND TRANSLATIONAL MEDICINE, 2023, 13 (12)

← 1 2 3 4 5 6 7 8 9 10 →